Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
20,788,527
-
Total 13F shares
-
153,897,366
-
Share change
-
+2,545,197
-
Total reported value
-
$3,692,333,792
-
Put/Call ratio
-
25%
-
Price per share
-
$24.00
-
Number of holders
-
202
-
Value change
-
+$66,232,342
-
Number of buys
-
102
-
Number of sells
-
75
Institutional Holders of Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NKTR) as of Q3 2017
As of 30 Sep 2017,
Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NKTR) was held by
202 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
153,897,366 shares.
The largest 10 holders included
OppenheimerFunds, Inc., PRIMECAP MANAGEMENT CO/CA/, BlackRock Inc., VANGUARD GROUP INC, Camber Capital Management LLC, STATE STREET CORP, WESTFIELD CAPITAL MANAGEMENT CO LP, Invesco Ltd., JANUS HENDERSON GROUP PLC, and NORGES BANK.
This page lists
202
institutional shareholders reporting positions in this security
for the Q3 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.